MORPHOSYS AG MorphoSys AG Share Price Deutsche Boerse AG
Equities
MOR2
US6177602025
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.5 EUR | -0.60% |
|
-2.94% | +96.43% |
| Sales 2024 * | 123M 133M 10.44B | Sales 2025 * | 325M 352M 27.7B | Capitalization | 2.57B 2.78B 219B |
|---|---|---|---|---|---|
| Net income 2024 * | -430M -465M -36.62B | Net income 2025 * | -116M -125M -9.88B | EV / Sales 2024 * | 21.7 x |
| Net Debt 2024 * | 89.28M 96.5M 7.6B | Net cash position 2025 * | 94.69M 102M 8.06B | EV / Sales 2025 * | 7.61 x |
| P/E ratio 2024 * |
-6.04
x | P/E ratio 2025 * |
-32.7
x | Employees | 464 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More press releases
More news
| 1 day | -0.60% | ||
| 1 week | -2.94% | ||
| Current month | +4.43% | ||
| 1 month | +0.61% | ||
| 6 months | +320.92% | ||
| Current year | +96.43% |
1 week
16.50
17.30
1 month
15.7017.30
Current year
7.5017.40
1 year
3.5617.40
3 years
2.9818.20
5 years
2.9835.00
10 years
2.9835.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 31/08/19 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 06/08/23 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 16/05/18 |
| Director/Board Member | 67 | 16/05/18 | |
Marc Cluzel
CHM | Chairman | 69 | 30/05/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/05/24 | 16.5 | -0.60% | 0 |
| 22/05/24 | 16.6 | 0.00% | 0 |
| 21/05/24 | 16.6 | -2.35% | 0 |
| 20/05/24 | 17 | -1.73% | 0 |
| 17/05/24 | 17.3 | +1.76% | 0 |
Delayed Quote Deutsche Boerse AG, May 23, 2024 at 08:05 am
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.2
EUR
Average target price
58.71
EUR
Spread / Average Target
-13.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.85% | 62.59B | |
| -1.78% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +12.58% | 26.21B | |
| -21.84% | 19.09B | |
| +4.26% | 13.08B | |
| +25.62% | 12.26B | |
| +28.18% | 12.05B |
- Stock Market
- Equities
- MOR Stock
- MOR2 Stock
